- Home
- SKIN vs NOTV Comparison
SKIN vs NOTV Comparison
Compare SKIN & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIN
- NOTV
- Stock Information
- Founded
- SKIN 1997
- NOTV 1974
- Country
- SKIN United States
- NOTV United States
- Employees
- SKIN N/A
- NOTV N/A
- Industry
- SKIN Package Goods/Cosmetics
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- SKIN Consumer Discretionary
- NOTV Health Care
- Exchange
- SKIN Nasdaq
- NOTV Nasdaq
- Market Cap
- SKIN 164.1M
- NOTV 137.5M
- IPO Year
- SKIN N/A
- NOTV 1997
- Fundamental
- Price
- SKIN $1.34
- NOTV $2.21
- Analyst Decision
- SKIN Hold
- NOTV Strong Buy
- Analyst Count
- SKIN 5
- NOTV 3
- Target Price
- SKIN $2.50
- NOTV $5.92
- AVG Volume (30 Days)
- SKIN 730.8K
- NOTV 552.5K
- Earning Date
- SKIN 03-12-2025
- NOTV 05-09-2025
- Dividend Yield
- SKIN N/A
- NOTV N/A
- EPS Growth
- SKIN N/A
- NOTV N/A
- EPS
- SKIN N/A
- NOTV N/A
- Revenue
- SKIN $334,294,000.00
- NOTV $475,114,000.00
- Revenue This Year
- SKIN $1.93
- NOTV $6.37
- Revenue Next Year
- SKIN $12.41
- NOTV $5.74
- P/E Ratio
- SKIN N/A
- NOTV N/A
- Revenue Growth
- SKIN N/A
- NOTV N/A
- 52 Week Low
- SKIN $0.91
- NOTV $1.23
- 52 Week High
- SKIN $4.48
- NOTV $11.20
- Technical
- Relative Strength Index (RSI)
- SKIN 45.76
- NOTV 35.56
- Support Level
- SKIN $1.25
- NOTV $2.72
- Resistance Level
- SKIN $1.45
- NOTV $3.35
- Average True Range (ATR)
- SKIN 0.11
- NOTV 0.31
- MACD
- SKIN 0.01
- NOTV -0.03
- Stochastic Oscillator
- SKIN 34.29
- NOTV 16.79
About SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.